Inho Kim
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 106
- Acute Myeloid Leukemia Research 52
- Hematopoietic Stem Cell Transplantation 32
- Multiple Myeloma Research and Treatments 31
- Chronic Myeloid Leukemia Treatments 16
- Oncology 53
- Co-authors
- Sung‐Soo Yoon (78 shared papers)Seonyang Park (57 shared papers)Youngil Koh (41 shared papers)Dong‐Yeop Shin (53 shared papers)Junshik Hong (44 shared papers)Ja Min Byun (38 shared papers)Shaji Kumar (7 shared papers)Michèle Cavo (7 shared papers)
- Journals
- Blood (22 papers)Annals of Hematology (17 papers)PLoS ONE (6 papers)Journal of Korean Medical Science (5 papers)Journal of Clinical Oncology (5 papers)
- Partner nations
- South KoreaUnited StatesEthiopia
In The Last Decade
Inho Kim
164 papers receiving 1.7k citations
Inho Kim's Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 877
- Genetics 283
- Oncology 516
- Otorhinolaryngology 51
- Internal Medicine 40
Countries citing papers authored by Inho Kim
This map shows the geographic impact of Inho Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inho Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inho Kim more than expected).
Fields of papers citing papers by Inho Kim
This network shows the impact of papers produced by Inho Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inho Kim. The network helps show where Inho Kim may publish in the future.
Co-authors
The 25 scholars most cited alongside Inho Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 183 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 256 |
| 2 | 2013 | 49 | |
| 3 | 2011 | 34 | |
| 4 | 2011 | 33 | |
| 5 | 2010 | 30 | |
| 6 | 2019 | 28 | |
| 7 | 2024 | 27 | |
| 8 | 2019 | 27 | |
| 9 | 2017 | 25 | |
| 10 | 2016 | 23 | |
| 11 | 2003 | 23 | |
| 12 | 2020 | 23 | |
| 13 | 2018 | 23 | |
| 14 | 2020 | 23 | |
| 15 | 2019 | 22 | |
| 16 | 2016 | 21 | |
| 17 | 2010 | 21 | |
| 18 | 2009 | 20 | |
| 19 | 2021 | 20 | |
| 20 | 2014 | 20 |
About Inho Kim
Inho Kim is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 183 papers that have together received 1.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (52 papers), Hematopoietic Stem Cell Transplantation (32 papers), Multiple Myeloma Research and Treatments (31 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers), Chronic Myeloid Leukemia Treatments (16 papers), Acute Lymphoblastic Leukemia research (15 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Lymphoma Diagnosis and Treatment (15 papers). The work is most often cited by research in Hematology (877 citations), Genetics (283 citations), Oncology (516 citations), Otorhinolaryngology (51 citations) and Internal Medicine (40 citations). Inho Kim has collaborated with scholars based in South Korea, United States and Ethiopia. Frequent co-authors include Sung‐Soo Yoon, Seonyang Park, Youngil Koh, Dong‐Yeop Shin, Junshik Hong, Ja Min Byun, Shaji Kumar, Michèle Cavo, Kenshi Suzuki and Simon J. Harrison. Their work appears in journals such as Blood, Annals of Hematology, PLoS ONE, Journal of Korean Medical Science and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.